Table 2.
CD40L-associated molecules in experimental atherosclerosis.
| Reference | Target molecule | Model | Diet (weeks) | Lesion size | Plaque stability | |
|---|---|---|---|---|---|---|
| Mach et al. (101) | CD40L | Anti-CD40L | Ldlr−/− | 12, HCD | Decreased | More stable |
| Lutgens et al. (102) | CD40L | Global KO | Apoe−/− | 23, chow diet | Decreased est., not early | More stable established lesions |
| Lutgens et al. (103) | CD40L | Anti-CD40L | Apoe−/− | 12, chow diet (starting at 5 weeks) | No effect | More stable |
| Lutgens et al. (103) | CD40L | Anti-CD40L | Apoe−/− | 12, chow diet (starting at 17 weeks) | No effect | More stable |
| Schönbeck et al. (104) | CD40L | Anti-CD40L | Ldlr−/− | 13, HCD (after 13 weeks HCD alone) | Decreased | More stable |
| Bavendiek et al. (105) | CD40L | Global KO | Ldlr−/− | 16, HCD | Decreased | More stable |
| Bavendiek et al. (105) | CD40L | Tx of Cd40l−/− BM | Ldlr−/− | 16, HCD | No effect | No effect |
| Zirlik et al. (69) | CD40 | Global KO | Ldlr−/− | 8 and 16, HCD | No effect | n/a |
| Lutgens et al. (106) | CD40 | Global KO | Apoe−/− | 23, chow diet | Decreased | More stable |
| Lutgens et al. (106) | CD40 | Tx of Cd40−/− BM | Ldlr−/− | 26, chow diet | Decreased | More stable |
| Lutgens et al. (106) | CD40-T6 | KI in MHC-II+ | Apoe−/− | 26, chow diet | Decreased | More stable |
| Lutgens et al. (106) | CD40-T2/3/5 | KI in MHC-II+ | Apoe−/− | 26, chow diet | No effect | No effect |
| Missiou et al. (107) | TRAF-1 | Global kO | Ldlr−/− | 8 and 18, HCD | Decreased | More stable |
| Stachon et al. (108) | TRAF-6 | Tx of Traf6−/− BM | Ldlr−/− | 18, HCD | No effect | No effect |
| Polykratis et al. (109) | TRAF-6fl | Tie2CreER | Apoe−/− | 10, HCD | Decreased in females | More stable |
| Polykratis et al. (109) | TRAF-6fl | LysMCre | Apoe−/− | 10, HCD | Increased | No effect |
| Missiou et al. (110) | TRAF-2 | Tx of Traf2−/− BM | Ldlr−/− | 18, HCD | No effect | No effect |
| Missiou et al. (110) | TRAF-5 | Global knockout | Ldlr−/− | 18, HCD | Increased | Unstable |
| Zirlik et al. (69) | Mac-1 | Global knockout | Ldlr−/− | 10, HCD | Decreased | More stable |
| Wolf et al. (56) | CD40L/Mac-1 binding | Peptide | Ldlr−/− | 20, HCD | Decreased | More stable |
| Yurdagul et al. (111) | α5β1 | Inhibitor of fibronectin | Apoe−/− | 8, HCD | Decreased | More stable |